Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 27 of 38 for:    MM-398

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03703063
Recruitment Status : Recruiting
First Posted : October 11, 2018
Last Update Posted : October 11, 2018
Sponsor:
Information provided by (Responsible Party):
Benaroya Research Institute

Brief Summary:
Using alternative neoadjuvant gemcitabine-nab-paclitaxel and nal-IRI with 5-Fluorouracil (5FU) and folinic acid (Leucovorin) regimens of localized cancer, we hope to ensure exposure of the cancer to a broader array of potentially active agents. Also, potentially improves patient tolerance and minimizes significant drug toxicity that could impair delivery of all treatment elements. Furthermore, it may enable prediction of superior to inferior treatment outcomes at an earlier point in the disease progress.

Condition or disease Intervention/treatment Phase
Pancreatic Adenocarcinoma Drug: Gemcitabine Drug: nab paclitaxel Drug: Onivyde Drug: Leucovorin Drug: 5-fu Phase 1

Detailed Description:

This research study is a Phase Ib clinical trial. It will assess the Safety, tolerability, and feasibility of gemcitabine-nab paclitaxel alternating with nal-IRI/5FU/leucovorin (NAPOLI) in de novo resectable and borderline resectable pancreatic cancer.

Subjects must have a newly diagnosed resectable or borderline resectable pancreatic ductal cancer and meet all inclusion/exclusion criteria.

Treatment consists of 4 week treatment cycles. Nab-paclitaxel and gemcitabine will be administered on days 1,8, and 15 with NAPOLI will be administered on days 1 and 15.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Resectable patients And Borderline resectable patients
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Alternating Neoadjuvant Gemcitabine-Nab-Paclitaxel and Nanoliposomal Irinotecan (Nal-IRI) With 5-Fluorouracil and Folinic Acid (Leucovorin) Regimens in Resectable and Borderline Resectable Pancreatic Cancer
Actual Study Start Date : September 17, 2018
Estimated Primary Completion Date : September 17, 2020
Estimated Study Completion Date : September 17, 2021


Arm Intervention/treatment
Experimental: Resectable patients
Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.
Drug: Gemcitabine
Administered by intravenous infusion over 30 minutes.
Other Name: Gemzar

Drug: nab paclitaxel
Administered by intravenous infusion over 30-40 minutes.
Other Name: Abraxane

Drug: Onivyde
Administered by intravenous infusion over 90 minutes.

Drug: Leucovorin
Administered by intravenous infusion over 30 minutes.

Drug: 5-fu
Administered by intravenous infusion over 46 hours.

Experimental: Borderline resectable patients
Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.
Drug: Gemcitabine
Administered by intravenous infusion over 30 minutes.
Other Name: Gemzar

Drug: nab paclitaxel
Administered by intravenous infusion over 30-40 minutes.
Other Name: Abraxane

Drug: Onivyde
Administered by intravenous infusion over 90 minutes.

Drug: Leucovorin
Administered by intravenous infusion over 30 minutes.

Drug: 5-fu
Administered by intravenous infusion over 46 hours.




Primary Outcome Measures :
  1. Treatment safety as assessed by CTCAE v4.03 [ Time Frame: An average of 1 year ]
    Toxicities are evaluated according to CTCAE v4.03


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 5 years ]
    OS is defined as the time between the date of enrollment and the date of death (whatever the cause).

  2. Progression free survival (PFS) [ Time Frame: 5 years ]
    PFS is defined as the time between the date of enrollment and the date of the first radiological and/or pathological progression. Progression is assessed by investigator according to RECIST v1.1 criteria.

  3. Response rate [ Time Frame: An average of 1 year ]
    Response rate will be assessed per RECIST v1.1 criteria and CA19-9 over the entire treatment period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Pathologically proven resectable or borderline resectable pancreatic cancer per current NCCN criteria (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp).
  2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0/1.
  3. Adequate bone marrow reserves as evidenced by:

    • absolute neutrophil count (ANC) ≥1,500 cells/μl without the use of hematopoietic growth factors; and
    • Platelet count ≥100,000 cells/μl; and
    • Hemoglobin ≥9 g/dL (blood transfusions are permitted for patients with hemoglobin levels below 9 g/dL).
  4. Adequate hepatic function as evidenced by:

    • Serum total bilirubin within normal range for the institution (biliary drainage is allowed for biliary obstruction); and
    • aspartate aminotransferase (AST) and alanine aminotransferase (ALT)

      • 2.5 x upper limit of normal (ULN) (≤5 x ULN is acceptable if liver metastases are present).
  5. Adequate renal function as evidenced by a serum creatinine ≤1.5 x ULN.
  6. At least 18 years of age.
  7. Women of child-bearing potential (defined as a sexually mature woman who (1) has not undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal for at least 24 consecutive months [i.e., has had menses at any time during the preceding 24 consecutive months]) must: Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis), or agree to use, and be able to comply with, effective contraception without interruption for 28 days prior to starting study medications (including dose interruptions) and for 3 months after last dose of study medication and Have a negative pregnancy test result at screening and agree to ongoing pregnancy testing at the Investigator's discretion during the course of the study. This applies even if the subject practices true abstinence from heterosexual contact.
  8. Male subjects must practice true abstinence or agree to use a condom during sexual contact with a female of childbearing potential or a pregnant female while on treatment (including during dose interruptions) with study medications and for 3 months following the last dose of study medication, even if he has undergone a successful vasectomy.

Exclusion Criteria:

  1. Prior therapy for pancreatic cancer (e.g., attempted surgery, chemotherapy, radiation therapy).
  2. Any contraindication to curative surgery.
  3. History of any second malignancy in the last 5 years except in-situ cancer or basal or squamous cell skin cancer. Subjects with history of other malignancies are eligible if they have been continuously disease free for at least 5 years.
  4. Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) less than 6 months before study participation.
  5. New York Heart Association (NYHA) Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure.
  6. Active infection or an unexplained fever >38.5°C during screening visit or on the first scheduled day of dosing in each cycle which, in the Investigator's opinion, might compromise the subject's participation in the trial or affect the study outcome. Subjects with tumor fever may be enrolled at the discretion of the Investigator.
  7. Known hypersensitivity to any of the components of nal-IRI, other liposomal products, fluoropyrimidines or leucovorin.
  8. Neuropathy > grade 1.
  9. Investigational therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study.
  10. Any other medical or social condition deemed by the Investigator to be likely to interfere with a subject's ability to sign informed consent, cooperate and/or participate in the study in any way, or interfere with the interpretation of the results.
  11. Inability or unwillingness to provide written informed consent.
  12. Patients who are not appropriate candidates for participation in this clinical study for any other reason as determined by the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03703063


Contacts
Layout table for location contacts
Contact: Vincent J Picozzi, MD 206-223-6193 Vincent.Picozzi@virginiamason.org

Locations
Layout table for location information
United States, Washington
Virginia mason medical Center Recruiting
Seattle, Washington, United States, 98101
Contact: Vincent J Picozzi, MD    206-223-6193    Vincent.Picozzi@virginiamason.org   
Principal Investigator: Vincent Picozzi, MD         
Sponsors and Collaborators
Benaroya Research Institute
Investigators
Layout table for investigator information
Principal Investigator: Vincent J Picozzi, MD Virginia mason medical Center

Layout table for additonal information
Responsible Party: Benaroya Research Institute
ClinicalTrials.gov Identifier: NCT03703063     History of Changes
Other Study ID Numbers: CRP17118
First Posted: October 11, 2018    Key Record Dates
Last Update Posted: October 11, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Benaroya Research Institute:
Pancreatic cancer
nal-IRI
NAPOLI

Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Pancreatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Gemcitabine
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs